Metropolitan Life Insurance Company (MetLife)’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,642	Closed	-$73.4K	–	2840
2021 Q3	$73.4K	Buy	+1,642	New	+$80.2K	﹤0.01%	2683
2021 Q2	–	Sell	-1,076	Closed	-$80.5K	–	2904
2021 Q1	$80.5K	Sell	1,076 -175	-14%	-$18.2K	﹤0.01%	2472
2020 Q4	$136K	Hold	1,251	–	–	﹤0.01%	2190
2020 Q3	$111K	Hold	1,251	–	–	﹤0.01%	2159
2020 Q2	$133K	Buy	1,251 +28	+2%	+$2.51K	﹤0.01%	2081
2020 Q1	$72.5K	Buy	+1,223	New	+$83K	﹤0.01%	2236
2019 Q4	–	Sell	-1,329	Closed	-$138K	–	2568
2019 Q3	$138K	Buy	1,329 +1,039	+358%	+$98.1K	﹤0.01%	2123
2019 Q2	$26.8K	Buy	+290	New	+$20.2K	﹤0.01%	2572
2018 Q4	–	Sell	-926	Closed	-$110K	–	2578
2018 Q3	$110K	Hold	926	–	–	﹤0.01%	2398
2018 Q2	$94.5K	Buy	+926	New	+$115K	﹤0.01%	2350
2017 Q3	–	Sell	-970	Closed	-$156K	–	2540
2017 Q2	$156K	Buy	+970	New	+$152K	﹤0.01%	2463

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SYRS Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 1,642 shares — an estimated $73.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SYRS in Q2 2017 and held it in 11 quarters. The position peaked at $156K in Q2 2017. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,642 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $73.4K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s Syros Pharmaceuticals, Inc. Common Stock position peaked at $156K in Q2 2017.
90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.